Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases

Executive Summary

Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it

You may also be interested in...



Lesson from Lilly’s Zyprexa Settlement: Be Proactive In Monitoring Sales Reps

Companies might shield themselves from claims of off-label drug marketing by adopting oversight procedures mandated in Lilly's corporate integrity agreement with HHS

Teva’s Generic Evista Launch Remains On Hold During Patent Trial

In second court-order delay, judge grants temporary restraining order, saying Lilly is likely to prevail in patent infringement trial.

BLA Exclusivity Would Ease Acquisitions And Improve R&D Focus, Lilly Says

Lilly has found another reason for follow-on biologics legislation to provide 14 years of data exclusivity for innovators: it will make the vetting process easier in mergers and acquisitions

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel